Online citations, reference lists, and bibliographies.
← Back to Search

Tumor Target Prostate Specific Membrane Antigen (PSMA) And Its Regulation In Prostate Cancer

A. Ghosh, W. Heston
Published 2004 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Prostate specific membrane antigen (PSMA), is a unique membrane bound glycoprotein, which is overexpressed manifold on prostate cancer as well as neovasculature of most of the solid tumors, but not in the vasculature of the normal tissues. This unique expression of PSMA makes it an important marker as well as a large extracellular target of imaging agents. PSMA can serve as target for delivery of therapeutic agents such as cytotoxins or radionuclides. PSMA has two unique enzymatic functions, folate hydrolase and NAALADase and found to be recycled like other membrane bound receptors through clathrin coated pits. The internalization property of PSMA leads one to consider the potential existence of a natural ligand for PSMA. In this review we have discussed the regulation of PSMA expression within the cells, and significance of its expression in prostate cancer and metastasis. © 2003 Wiley‐Liss, Inc.
This paper references
Prostate-specific membrane antigen expression in normal and malignant human tissues.
D. A. Silver (1997)
Role of carbohydrate moieties on biological function of prostate specif membrane antigen/folate hydrolase/glutamate carboxypeptidase II
A Ghosh (2003)
10.1016/S0167-4838(97)00008-3
Structure of membrane glutamate carboxypeptidase.
N. Rawlings (1997)
Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity.
G. Anilkumar (2003)
10.1016/0962-8924(94)90220-8
Targeting of membrane proteins to endosomes and lysosomes.
I. Sandoval (1994)
Role of carbohydrate residues on the folate hydrolase activity of the prostate specific membrane antigen
A Ghosh (2003)
Human prostate specific membrane antigen (PSMA) is naturally expressed as a non covalent dimer
N Schulke (2001)
10.1007/978-1-4613-1835-4_23
Role of vitamin B12 and folate deficiencies in carcinogenesis.
I. Eto (1986)
10.1016/S0090-4295(96)00184-7
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.
G. Wright (1996)
10.1002/PROS.10289
Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen
A. Ghosh (2003)
10.1016/0076-6879(83)98155-7
[22] Receptor-mediated endocytosis of epidermal growth factor
H. Haigler (1983)
10.1046/j.1471-4159.1997.69062270.x
Molecular Cloning of a Peptidase Against N‐Acetylaspartylglutamate from a Rat Hippocampal cDNA Library
T. Bzdega (1997)
10.1006/MTHE.2002.0682
Novel prostate-specific promoter derived from PSA and PSMA enhancers.
S. Lee (2002)
Dipeptidyl Peptidase IV ( CD 26 ) Gene Expression in Enterocyte-like Colon Cancer Cell Lines HT-29 and Caco-2
Dalila DarmoulS (2001)
10.1093/NAR/29.21.4274
SOX7 transcription factor: sequence, chromosomal localisation, expression, transactivation and interference with Wnt signalling.
W. Takash (2001)
10.1007/s003350010240
Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase
D. Bacich (2001)
10.1038/bjc.1995.377
Prostate-specific membrane antigen: evidence for the existence of a second related human gene.
J. Leek (1995)
10.1073/PNAS.88.5.1918
Signals for retention of transmembrane proteins in the endoplasmic reticulum studied with CD4 truncation mutants.
J. Shin (1991)
A novel cytoplasmic tail MXXXL motif mediates the internalization and lysosomal targeting of prostate specific membrane antigen
S Rajasekaran (2003)
10.1073/PNAS.93.19.10134
Human gamma-glutamyl hydrolase: cloning and characterization of the enzyme expressed in vitro.
R. Yao (1996)
10.1091/MBC.10.3.677
Cluster of differentiation antigen 4 (CD4) endocytosis and adaptor complex binding require activation of the CD4 endocytosis signal by serine phosphorylation.
C. Pitcher (1999)
10.1093/emboj/17.5.1304
A di‐leucine‐based motif in the cytoplasmic tail of LIMP‐II and tyrosinase mediates selective binding of AP‐3
S. Höning (1998)
10.1074/jbc.274.5.3141
A Leucine-based Determinant in the Epidermal Growth Factor Receptor Juxtamembrane Domain Is Required for the Efficient Transport of Ligand-Receptor Complexes to Lysosomes*
S. J. Kil (1999)
10.1016/0092-8674(92)90636-Q
A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains
F. Letourneur (1992)
10.1016/S0167-4781(98)00200-0
Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene.
D. S. O'Keefe (1998)
10.1016/0306-9877(95)90121-3
Folic acid as a cancer-preventing agent.
E. Jennings (1995)
10.1074/jbc.272.49.31006
Cloning and Characterization of a Novel Peptidase from Rat and Human Ileum*
B. Shneider (1997)
10.1016/s0021-9258(18)42906-7
Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation.
D. Darmoul (1992)
10.1146/ANNUREV.IY.11.040193.003035
The molecular cell biology of interferon-gamma and its receptor.
M. A. Farrar (1993)
Prostate-specific membrane antigen expression in normal andmalignant human tissues
DA Silver (1997)
10.1016/S0962-8924(96)10057-X
Protein sorting by tyrosine-based signals: adapting to the Ys and wherefores.
M. Marks (1997)
10.1146/ANNUREV.PH.43.030181.001323
Receptor-mediated endocytosis of hormones in cultured cells.
I. Pastan (1981)
Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression.
S. Su (1995)
10.1016/S0093-7754(03)00358-0
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
N. Bander (2003)
Receptor-mediated endocytosis of epidermal growth factor.
H. Haigler (1983)
10.1074/JBC.273.32.20417
Folylpoly-gamma-glutamate carboxypeptidase from pig jejunum. Molecular characterization and relation to glutamate carboxypeptidase II.
C. Halsted (1998)
Role of carbohydrate residues on the folate hydrolase activity of the
A Ghosh
10.1016/B978-0-12-150401-4.50012-2
IL-6 Receptor
T. Taga (1990)
10.1007/978-3-642-72045-1_9
Intracellular transport of molecules engaged in the presentation of exogenous antigens.
T. Nordeng (1998)
10.1074/JBC.M009895200
Expression of CaT-like, a Novel Calcium-selective Channel, Correlates with the Malignancy of Prostate Cancer*
U. Wissenbach (2001)
Constitutive and antibody-induced internalization of prostate-specific membrane antigen.
H. Liu (1998)
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.
R. Israeli (1993)
10.1016/s0021-9258(17)45854-6
Involvement of dileucine motifs in the internalization and degradation of the insulin receptor.
C. Haft (1994)
10.1046/j.1464-410x.1998.00599.x
Prostate-specific membrane antigen.
B. Maraj (1998)
10.1074/jbc.274.30.20826
Molecular Cloning of Transferrin Receptor 2
H. Kawabata (1999)
10.1146/ANNUREV.CB.09.110193.001021
Signal-dependent membrane protein trafficking in the endocytic pathway.
I. S. Trowbridge (1993)
10.1016/S0167-4889(98)00056-1
Clathrin and adaptors.
J. Hirst (1998)
10.1016/S0955-0674(97)80029-4
The trans-Golgi network: a late secretory sorting station.
L. Traub (1997)
10.1006/GENO.1995.0019
Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11.
C. Rinker-Schaeffer (1995)
10.1074/jbc.271.10.5487
A Di-leucine Motif and an Upstream Serine in the Interleukin-6 (IL-6) Signal Transducer gp130 Mediate Ligand-induced Endocytosis and Down-regulation of the IL-6 Receptor (*)
E. Dittrich (1996)
specific membrane antigen
CR Haft (1994)
Volumeregulated chloride conductance in the LNCaP human prostate cancer cell line
YM Shuba (2000)
Fully human anti-PSMA antibodies for prostate cancer therapy
D Ma (2003)
10.1152/AJPCELL.2000.279.4.C1144
Volume-regulated chloride conductance in the LNCaP human prostate cancer cell line.
Y. Shuba (2000)



This paper is referenced by
10.1159/000509974
Comparison of 68Ga-PSMA-I/T PET-CT and Multiparametric MRI for Locoregional Staging of Prostate Cancer Patients: A Pilot Study
Sinan Çelen (2020)
10.4274/nts.2018.024
Prostate-Specific Membrane Antigene PET/CT in Biochemical Recurrence
U. Elboğa (2018)
10.2967/jnumed.117.191031
PSMA Ligands for PET Imaging of Prostate Cancer
S. Schwarzenböck (2017)
10.1007/s00268-005-0544-5
Expression of Prostate-Specific Membrane Antigen in Normal and Malignant Human Tissues
Y. Kinoshita (2005)
10.1002/adma.201305842
Combined detection of cancer cells and a tumor biomarker using an immunomagnetic sensor for the improvement of prostate-cancer diagnosis.
Hung-Wei Yang (2014)
10.23736/S0393-2249.18.03152-1
Prostate specific membrane antigen: the role in salvage lymph node dissection and radio-ligand therapy.
W. M. Ong (2018)
10.1007/s11701-016-0641-5
Applications of indocyanine green in robotic urology
A. Bates (2016)
10.1016/j.bmcl.2015.04.092
Prostate tumor specific peptide-peptoid hybrid prodrugs.
Jiyoun Lee (2015)
10.1053/J.SEMNUCLMED.2019.02.001
New Targets for PET Molecular Imaging of Prostate Cancer.
E. Mena (2019)
10.1016/j.ymeth.2017.07.009
New aspects of molecular imaging in prostate cancer.
F. Ceci (2017)
10.1039/c002524k
Simultaneous electrochemical detection of both PSMA (+) and PSMA (-) prostate cancer cells using an RNA/peptide dual-aptamer probe.
Kyoungin Min (2010)
10.3390/ijms15046046
PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy
M. Rybalov (2014)
10.1007/s00117-014-2792-6
68Ga-PSMA als neuer Tracer für die Evaluation des Prostatakarzinoms
M. Avanesov (2014)
10.1007/s00259-015-3302-4
68Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer
C. Sachpekidis (2015)
10.1586/14789450.2013.827408
Proteomics of human prostate cancer biospecimens: the global, systems-wide perspective for Protein markers with potential clinical utility
S. Garbis (2013)
10.1007/s00262-009-0723-6
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy
V. Cereda (2009)
10.1016/j.nano.2020.102213
Real time ultrasound molecular imaging of prostate Cancer with PSMA-targeted Nanobubbles.
R. Perera (2020)
10.1016/B978-0-12-800276-6.00009-7
Targeted Adenoviral Vectors I
I. Dmitriev (2016)
10.1097/MNM.0000000000000514
Have we overcome choline PET/CT for early detection of prostate cancer recurrence?
W. Fendler (2016)
10.1016/j.ejpb.2014.03.016
RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes for enhanced intracellular drug delivery to hepsin-expressing cancer cells.
M. Kang (2014)
10.1016/j.jconrel.2014.05.035
Prostate cancer relevant antigens and enzymes for targeted drug delivery.
Ashutosh Barve (2014)
10.1096/fj.12-225102
Glutamate carboxypeptidase II is not an amyloid peptide‐degrading enzyme
J. Alt (2013)
Automated Multiplexed Electrochemiluminescence based Immunoarrays for Prostate Cancer Biomarker Protein Detection & Genotoxic Screening Assays Using Electrochemiluminescence and LC-MS/MS
Karteek Kadimisetty (2017)
Concurrent detection and isolation of cellular and molecular biomarkers
Wanfeng Huang (2016)
10.2967/jnumed.114.149062
Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates
S. Banerjee (2015)
10.4137/BECB.S34255
A Review of Imaging Methods for Prostate Cancer Detection
Saradwata Sarkar (2016)
10.1111/j.1464-410X.2012.11444.x
Angiogenesis in prostate cancer: onset, progression and imaging
G. Russo (2012)
10.3390/ijms16059573
In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles
Yunkai Zhu (2015)
10.1186/s13550-018-0440-2
Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity
Martina Wirtz (2018)
10.1158/1055-9965.EPI-07-0511
Prostate-Specific Membrane Antigen Expression Is a Potential Prognostic Marker in Endometrial Adenocarcinoma
P. Mhawech-Fauceglia (2008)
10.1517/14728222.9.3.561
Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen
S. Slovin (2005)
10.1007/s00432-019-02867-6
T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances
Lin Yu (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar